CASC3 and Miyoshi myopathy: The combination therapy with BTZ, lenalidomide and dexamethasone (VRd) constitutes the first-line regimen for relapsed/refractory as well as newly diagnosed MM in terms of its high impact on overall survival (Ibata et al., 2016[62]).